The potential combinational immunotherapiesfor treatment of hepatocellular carcinoma

The treatment choices available for hepatocellular carcinoma (HCC) are limited and unsatisfactory. Recent improvements in our understanding of the mechanism involving immune checkpoints, including programmed cell death protein 1 (PD1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-as...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Shuai, Bai, Xue, Chen, Shujie, Song, Yang, Liu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562285/
https://www.ncbi.nlm.nih.gov/pubmed/34805871
http://dx.doi.org/10.1016/j.jimed.2019.09.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562285/
https://www.ncbi.nlm.nih.gov/pubmed/34805871
http://dx.doi.org/10.1016/j.jimed.2019.09.006

Ejemplares similares